The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...

Novo Nordisk's GLP-1 receptor ... alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use for the versatile drug class. The small, 48-subject study ...

The rise of GLP-1 weight loss drugs represents a shift in the way consumers ... The Acosta Group study confirms the growing interest in GLP-1 products and shows how this therapeutic option has ...

lower-dose care model to U.S. employers seeking sustainability As GLP-1 adoption grows among U.S. employers, the study points to a path toward meaningful outcomes without escalating drug costs.

Study presented at DDW ... trial design to support drug development. The study titled, "A Genetic Risk Score Associated with Nausea Resulting from GLP-1 Agonist Treatment: A Post-Hoc Analysis ...

Higher body appreciation was highlighted as a protective factor against GLP-1 use. However, it is important to note that the study's cross-sectional design means these findings are correlational ...

This retrospective study suggests there is a cardioprotective effect of GLP-1RA compared ... antiarrhythmic drug use, cardioversion, or repeat ablation by 1 year. Similarly, in PULSED AF, around ...

With the rapid increase in GLP-1 receptor agonist use in the population ... So maybe it's an excellent drug to employ, but maybe not in the first 6 months." The study involved retrospective ...

The observational, real-life retrospective cohort study found that in adults with obesity and type 2 diabetes but no prior heart disease, glucagon-like peptide-1 receptor agonists (GLP-1RAs ...